# OnCo record nct03801525 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03801525/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03801525", "NCT03801525" ;
  schema:name "Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)"@en ;
  schema:description "A phase 2/3 trial of Umbralisib and Venetoclax in Chronic lymphocytic leukaemia, run by TG Therapeutics, Inc., recorded as terminated on the registry."@en ;
  schema:url <https://onco.cc/trials/nct03801525/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03801525> ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2/3" ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:drugs <https://onco.cc/drugs/umbralisib/>, <https://onco.cc/drugs/venetoclax/> .